Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies

Summary Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the second most frequent cause of cancer-related mortality worldwide. The multikinase inhibitor sorafenib is the only treatment option for advanced HCC. Due to tumor heterogeneity, its efficacy greatly varies between patients and is limited due to adverse effects and drug resistance. Current in vitro models fail to recapitulate key features of HCCs. We report the generation of long-term organoid cultures from tumor needle biopsies of HCC patients with various etiologies and tumor stages. HCC organoids retain the morphology as well as the expression pattern of HCC tumor markers and preserve the genetic heterogeneity of the originating tumors. In a proof-of-principle study, we show that liver cancer organoids can be used to test sensitivity to sorafenib. In conclusion, organoid models can be derived from needle biopsies of liver cancers and provide a tool for developing tailored therapies.

[1]  Tom R. Gaunt,et al.  Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov Models , 2012, Human mutation.

[2]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[3]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[4]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[5]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[6]  Cyriac Kandoth,et al.  Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer , 2018, Cell.

[7]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Lau,et al.  Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study , 2016, Oncotarget.

[9]  Leyla Isik,et al.  Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. , 2009, Cancer research.

[10]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[11]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[12]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[13]  M. Kudo,et al.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial , 2017, The Lancet.

[14]  H. Edmondson,et al.  Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies , 1954, Cancer.

[15]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[16]  Hans Clevers,et al.  Modeling Development and Disease with Organoids , 2016, Cell.

[17]  B. Taylor,et al.  deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.

[18]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[19]  Hans Clevers,et al.  Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.

[20]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[21]  Mark D Robinson,et al.  edgeR for differential RNA-seq and ChIP-seq analysis: an application to stem cell biology. , 2014, Methods in molecular biology.

[22]  Hans Clevers,et al.  A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity , 2018, Cell.

[23]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[24]  Melissa P. Murray,et al.  The Genomic Landscape of Male Breast Cancers , 2016, Clinical Cancer Research.

[25]  Chen-Chieh Yang,et al.  Current systemic treatment of hepatocellular carcinoma: A review of the literature. , 2015, World journal of hepatology.

[26]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.

[27]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[28]  Bon-Kyoung Koo,et al.  Human Primary Liver Cancer -derived Organoid Cultures for disease modelling and drug screening , 2017, Nature Medicine.

[29]  L. Pusztai,et al.  Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.

[30]  Keith A. Boroevich,et al.  Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer , 2016, Nature Genetics.

[31]  Hans Clevers,et al.  Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver , 2015, Cell.

[32]  Hans Clevers,et al.  Organoids in cancer research , 2018, Nature Reviews Cancer.

[33]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[34]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[35]  H. Iishi,et al.  Retaining cell–cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer , 2011, Proceedings of the National Academy of Sciences.

[36]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[37]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[38]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[39]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[40]  C. Sander,et al.  3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets , 2017, Genome Medicine.

[41]  S. Thorgeirsson,et al.  Functional and genetic deconstruction of the cellular origin in liver cancer , 2015, Nature Reviews Cancer.

[42]  J. Llovet,et al.  Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design , 2014, Clinical Cancer Research.

[43]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[44]  Toshio Uraoka,et al.  A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. , 2016, Cell stem cell.

[45]  Hans Clevers,et al.  Designer matrices for intestinal stem cell and organoid culture , 2016, Nature.

[46]  Davide Prandi,et al.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. , 2017, Cancer discovery.

[47]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[48]  Y. N. Park,et al.  The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. , 2009, Journal of hepatology.

[49]  N. Socci,et al.  Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity , 2015, Nature Biotechnology.